Incyte Reports Strong Q1 2026
summarizeSummary
2026 8-K Incyte 21% 20% Jakafi, Opzelura, Hematology/Oncology robust commercial execution. Critically, Phase 3 povorcitinib nonsegmental vitiligo, primary endpoints 2 , FDA NDA povorcitinib hidradenitis suppurativa. pipeline advancements, 2026 strengthened cash position, future growth de-risk development programs. Investors regulatory decisions launches povorcitinib Jakafi XR.
check_boxKey Events
-
Strong Q1
21% $1.27 20% $1.10 year-over-year. GAAP net income $303.3 million, diluted EPS $1.47.
-
Key Product Sales Growth
Jakafi net sales 7% $758 million, Opzelura net sales 20% $143 million, Hematology and Oncology portfolio 116% $204 million.
-
Povorcitinib Pipeline Advancements
Phase 3 povorcitinib nonsegmental vitiligo, primary endpoints 2 , H1 2027 . FDA New Drug Application povorcitinib moderate to severe hidradenitis suppurativa, late 2026 EU Q1 2027 U.S.).
-
Reaffirmed 2026 Financial Guidance
2026 financial guidance , continued performance.
auto_awesomeAnalysis
2026 8-K Incyte 21% 20% Jakafi, Opzelura, Hematology/Oncology robust commercial execution. Critically, Phase 3 povorcitinib nonsegmental vitiligo, primary endpoints 2 , FDA NDA povorcitinib hidradenitis suppurativa. pipeline advancements, 2026 strengthened cash position, future growth de-risk development programs. Investors regulatory decisions launches povorcitinib Jakafi XR.
この提出時点で、INCYは$92.00で取引されており、市場はNASDAQ、セクターはIndustrial Applications And Services、時価総額は約$190.5億でした。 52週の取引レンジは$57.77から$112.29でした。 この提出書類はポジティブの市場センチメント、重要度スコア8/10と評価されました。